Traws Pharma, Inc.: Myelodysplastic Syndromes trials

The registry lists 12 Myelodysplastic Syndromes studies with Traws Pharma, Inc. as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 6Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATerminatedNCT02562443Phase 3
• Three Dosing Schedules of Oral Rigosertib in MDS PatientsWithdrawnNCT02075034Phase 1
• Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
• Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
• Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsCompletedNCT01904682Phase 2
• Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeCompletedNCT01584531Phase 2
• Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
• Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeCompletedNCT01048619Phase 1
• Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskCompletedNCT00906334Phase 2
• Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)WithdrawnNCT00867061Phase 1/2
• Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
• Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1